Insmed Earnings Call Highlights BRINSUPRI-Fueled Momentum

Insmed ((INSM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Insmed’s latest earnings call struck a notably upbeat tone, with management leaning on a standout BRINSUPRI launch, strong payer and patient metrics, and a solid balance sheet to frame a confident growth story. Risks around the fading “ready-and-waiting” surge, international pricing uncertainty, and future payer pressures were acknowledged, but executives argued the current trajectory supports a path to profitability by 2027.

BRINSUPRI Launch Delivers Powerful Sequential Growth

BRINSUPRI’s commercial debut continues to impress, with Q1 revenue up 44% sequentially on top of a strong prior quarter. Across its first two full quarters on the market, the drug generated roughly $350 million in combined revenue, giving management sufficient visibility to reiterate its full‑year 2026 target of at least $1.0 billion in global BRINSUPRI sales.

Payer Approvals High and Authorizations Rapid

Insmed highlighted payer dynamics as a key competitive advantage, noting that nearly 90% of patients processed through specialty pharmacies have received coverage approvals since launch. For the majority of patients, time to payer authorization has been under one week, a pace management said is meaningfully better than its internal expectations and supportive of continued adoption.

Patient Support, Refills and Adherence Trending Strong

More than 80% of BRINSUPRI users are enrolled in the company’s inLighten patient support program, helping reduce friction for new starts and ongoing therapy. Refill cadence is running at close to every 30 days versus an industry benchmark near 37 days, and continuation rates are tracking slightly above six‑month statin levels of around 70%, pointing to encouraging early adherence.

Prescriber Base Broadens Across U.S. Pulmonologists

The prescriber footprint continues to expand, with cumulative BRINSUPRI prescribers topping 5,000 by quarter‑end, representing over a quarter of U.S. pulmonologists. Notably, more than 20% of these physicians have already written prescriptions for at least five patients, and management reported that many initially low‑volume prescribers are beginning to increase their prescribing depth over time.

ENCORE Data Signals Larger ARIKAYCE Opportunity

ARIKAYCE’s Phase IIIb ENCORE trial delivered a statistically significant win on its primary endpoint, a patient‑reported respiratory symptom score. Importantly, earlier treatment in ENCORE achieved durable culture conversion in over 80% of patients, far above the roughly 30% conversion seen in the prior refractory CONVERT study, while also showing better tolerability and lower discontinuations in this earlier‑treatment setting.

TPIP Pipeline Advances Through Late‑Stage Studies

Insmed’s inhaled treprostinil program, TPIP, is progressing through a broad Phase III agenda, including PAH, PH‑ILD, PPF and IPF trials. The PALM PAH study opened its first site and PALM‑ILD has randomized patients across seven countries, while open‑label PAH data show about a quarter of participants titrating above 640 mcg and some reaching 1,280 mcg, with more detailed extension results expected in the third quarter of 2026.

Balance Sheet Strength and Path to Profitability

The company ended the quarter with approximately $1.2 billion in cash, cash equivalents and marketable securities, and said underlying cash burn remained consistent with recent history. Management reiterated its expectation of reaching sustainable cash‑flow positivity in 2027 without raising additional capital, assuming no major business development deals that would expand the expense base.

Improving Gross Margins from BRINSUPRI Mix

Cost of product revenues in the quarter totaled $47.4 million, representing 15.5% of total revenues, a percentage that marks an improvement on historical performance. Insmed attributed the stronger margin profile to the growing contribution from BRINSUPRI, which carries a favorable gross margin and is increasingly shaping the company’s overall revenue mix.

Ready‑and‑Waiting Demand Surge Fades

Management cautioned that the launch’s early boost from “ready‑and‑waiting” patients is largely behind the company, with about 3,500 such starts in Q4 and 1,500 in Q1 out of roughly 9,000 and 7,800 total new patients, respectively. With this backlog essentially cleared, executives signaled that Q2 will be the first period where growth must be driven primarily by organic demand rather than pent‑up pre‑approval interest.

New Patient Adds Step Down from Q4 Peak

Total new BRINSUPRI patients in Q1 came in below the Q4 baseline, reflecting the exceptional influx of ready‑and‑waiting patients at launch rather than a deterioration in underlying demand. Insmed framed the Q1 performance as a normalization toward a more sustainable run‑rate, while acknowledging that investors will now focus more closely on sequential trends as the launch transitions into a more mature phase.

MFN Policy Clouds International Launch Plans

Insmed has paused or constrained certain European launch activities due to uncertainty created by U.S. MFN pricing policy, which can link domestic prices to lower international levels. Management warned that aggressive moves into Europe risk undermining U.S. pricing, so the company plans to tread cautiously on global expansion until there is more clarity, adding a layer of timing risk to the ex‑U.S. growth story.

Payer Policy Risk Looms Despite Strong Start

While current approval rates are robust, executives acknowledged that payer policies can evolve over time and may become more restrictive as BRINSUPRI grows. Potential tighter prior authorization rules or changes in contracting could compress the roughly 90% approval rate seen today, making it important for Insmed to demonstrate durable clinical and economic value to maintain favorable coverage.

Discontinuation Trends Still Not Fully Understood

Analysts pressed for more detail on discontinuation dynamics, noting implied six‑month drop‑off rates in the low‑20% range for early cohorts. The company declined to break down discontinuations by cause and admitted limited visibility into factors such as payer decisions or out‑of‑pocket resets, though it emphasized that overall continuation remains slightly better than widely used statin benchmarks.

Higher Operating Spend Fuels Launch and R&D

R&D and SG&A expenses rose year over year as Insmed invested in the U.S. BRINSUPRI launch and advanced its pipeline, including TPIP and ARIKAYCE programs. Management guided that spending should moderate relative to revenue as the topline ramps, but reiterated that elevated near‑term investment is critical to cementing BRINSUPRI’s position and sustaining the company’s late‑stage clinical momentum.

Competitive Landscape Creates TPIP Execution Risk

The company acknowledged a competitive field for treprostinil‑based and other therapies targeting pulmonary indications, with rival programs potentially advancing quickly or reading out pivotal data. Insmed argued TPIP’s profile and inhaled delivery confer differentiation, yet stressed that the ultimate commercial opportunity will hinge on producing compelling Phase III evidence and navigating evolving market dynamics.

Guidance Reinforced by Strong Early Launch Metrics

Insmed reiterated guidance for BRINSUPRI to deliver at least $1.0 billion in global net revenue this year, supported by 44% sequential growth and about $350 million in revenue from its first two full quarters. The company confirmed gross‑to‑net ranges, reported Q1 gross margin consistent with guidance, emphasized that cash burn should decline as revenues build, and reaffirmed its goal of reaching sustainable cash‑flow positivity in 2027 without new capital.

Insmed’s earnings call painted the picture of a company in execution mode, with BRINSUPRI’s early momentum and ARIKAYCE and TPIP pipeline progress anchoring a bullish narrative. While the fading launch backlog, policy risks and competition introduce real uncertainties, management’s reaffirmed guidance and strong financial footing suggest investors will focus on whether organic demand and late‑stage data can keep the growth story on track.